BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//California Life Sciences - ECPv6.17.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:California Life Sciences
X-ORIGINAL-URL:https://www.califesciences.org
X-WR-CALDESC:Events for California Life Sciences
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260928T084500
DTEND;TZID=America/Los_Angeles:20260928T163000
DTSTAMP:20260817T171524Z
CREATED:20260817T163834Z
LAST-MODIFIED:20260817T171524Z
UID:10001155-1790585100-1790613000@www.califesciences.org
SUMMARY:Nonclinical safety pharmacology studies for IND and regulatory filings
DESCRIPTION:This workshop will provide an integrated overview of how safety pharmacology studies support IND‑enabling development\, with a focus on regulatory expectations\, evolving scientific practices\, and translational decision‑making. Topics will begin with an overview of current regulatory guidance and agency expectations for safety pharmacology programs\, setting the framework for study scope\, timing\, and interpretation. \nCore systems safety pharmacology will be addressed in depth\, including nonclinical cardiovascular (CV) safety assessment\, with discussion of study design\, endpoints\, and integration with clinical risk assessment. This will be complemented by a clinical pharmacology perspective on CV safety\, including TQT studies\, criteria for TQT waivers\, and strategies for leveraging nonclinical and early clinical data to support regulatory decisions. \nCentral nervous system (CNS) safety will be covered through focused discussions on seizure liability\, the use of EEGs\, and interpretation of neurophysiologic signals in both discovery and IND‑enabling contexts. Respiratory safety pharmacology will be reviewed\, highlighting standard approaches\, key endpoints\, and relevance to human risk. \nBroader safety pharmacology considerations beyond the core battery will be discussed\, including evaluation of CNS\, brain\, gastrointestinal\, renal\, and related organ system effects\, with emphasis on fit‑for‑purpose study design and data integration. The workshop will conclude with emerging approaches\, featuring novel safety pharmacology studies that have elucidated Nav1.7‑associated dysautonomia\, illustrating how targeted mechanistic assessments can inform clinical safety and enhance translational understanding. \nREGISTER
URL:https://www.califesciences.org/event/nonclinical-safety-pharmacology-studies-for-ind-and-regulatory-filings/
LOCATION:1221 Chess Drive\, 1221 Chess Dr\, Foster City\, CA\, 94404
CATEGORIES:Industry Supported
ATTACH;FMTTYPE=image/png:https://www.califesciences.org/wp-content/uploads/2025/12/NorCal-Industry-Event.png
END:VEVENT
END:VCALENDAR